Abstract 250P
Background
Seminoma is the most common type of germ cell tumors representing 95% of all testicular neoplasm with mean age at diagnosis of 39 years. The standard treatment modality for stage I/II is orchidectomy with high cure rate.There is an active debate regarding the use of adjuvant therapy in stage I/II due to the high relapse rate and potential for overtreatment with serious systemic side effects. The aim of this study is to assess the impact of adjuvant treatment in stage I and stage II seminoma comparing the young and adolescents to older age groups.
Methods
Data of 11718 patients diagnosed with seminoma stage I/II were obtained from the Surveillance, Epidemiology, and End Results (SEER) program from 2000 to 2020. They were grouped by age at diagnosis into younger than 25 years (young age group), 25 to 49 years ( middle age group) and older than 50 years (old age group). SPSS 23 was used for data analysis, Kaplan-Meier curve and log rank test for survival analysis.
Results
Patients treated surgically with no systemic therapy had 5-year relative survival of 99,4% compared to adjuvant chemotherapy (98.3%) and adjuvant radiotherapy(100%), P<0.0001. The middle age group had quite similar 5-year relative survival compared to the young age group and the elderly (99.5%, 99.3% and 99%; P<0.0001). In the young age group the 5-year relative survival was 99.9% with orchidectomy, 97.4% with adjuvant chemotherapy and 100% with adjuvant radiotherapy (p <0.0001). In the middle age group, the 5-year relative survival was 99.2% with surgery with no systemic therapy, 98.4% with adjuvant chemotherapy and 99,9% with adjuvant radiotherapy (p <0.0001) while the old age group had 5-year relative survival of 98.9% for orchidectomy, 97.5% with adjuvant chemotherapy and 99.6% with adjuvant radiotherapy(p <0.0001).
Conclusions
The use of adjuvant chemotherapy and radiotherapy for clinical stage I and stage II testicular seminoma came statistically significant. However, adjuvant systemic therapy has very limited survival benefit compared to surgical management with no systemic therapy which discourage the use of adjuvant therapy for less systemic side effects with similar overall survival across different age groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract